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Summary
Background: Tegoprazan is a novel potassium‐competitive acid blocker that has a
fast onset of action and can control gastric pH for a prolonged period, which could
offer clinical benefit in acid‐related disorders.
Aim: To confirm the non‐inferiority of tegoprazan to esomeprazole in patients with
erosive oesophagitis (EE).
Methods: In this multicentre, randomised, double‐blind, parallel‐group comparison
study, 302 Korean patients with endoscopically confirmed EE (Los Angeles Classification
Grades A‐D) were randomly allocated to either tegoprazan (50 or 100 mg) or esomepra-
zole (40 mg) treatment groups for 4 or 8 weeks. The primary endpoint was the
cumulative proportion of patients with healed EE confirmed by endoscopy up to
8 weeks from treatment initiation. Symptoms, safety and tolerability were also assessed.
Results: The cumulative healing rates at week 8 were 98.9% (91/92), 98.9% (90/91) and
98.9% (87/88) for tegoprazan 50 mg, tegoprazan 100 mg and esomeprazole 40 mg, respec-
tively. Both doses of tegoprazan were non‐inferior to esomeprazole 40 mg. The incidence
of adverse eventswas comparable among the groups, and tegoprazanwaswell‐tolerated.
Conclusion: Once daily administration of tegoprazan 50 or 100 mg showed non‐in-
ferior efficacy in healing EE and tolerability to that of esomeprazole 40 mg.
The complete list of affiliations is listed in Appendix 1.
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1 | INTRODUCTION
Gastro‐oesophageal reflux disease (GERD) is a prevalent digestive
disease that results from reflux of gastric contents into the oesopha-
gus.1,2 The prevalence of GERD in East Asian countries is increasing,
and is reported to be 4.5%‐15.7%3,4 Population‐based studies have
shown that the prevalence of symptom‐based GERD in East Asia
was 5.2%‐8.5% from 2005 to 2010. According to the Korean
National Health Insurance claim, data also show that the prevalence
of GERD in Korea is increasing rapidly from 4.6% to 7.3% between
2005 and 2008.5,6
The spectrum of GERD includes erosive oesophagitis (EE) and non‐
erosive reflux disease (NERD). EE is characterised by the presence of
oesophageal mucosal erosions induced by the reflux of gastric con-
tents from the stomach, which can be diagnosed by endoscopy. Cur-
rently, proton‐pump inhibitors (PPIs) are the first‐line drug for treating
EE and controlling symptoms.7 Studies in patients with EE have shown
high healing rates (88%‐96%) after 8‐week treatment with a PPI once
daily.8–10 However, some patients may have endoscopic evidence of
oesophagitis and/or reflux symptoms despite PPI therapy.11–13
Tegoprazan, (S)‐4‐((5,7‐difluorochroman‐4‐yl)oxy)‐N,N,2‐trimethyl‐
1H‐benzo[d]imidazole‐6‐carboxamide, was developed in South Korea
by CJ Healthcare Corp. It is a novel, potent, and highly selective
potassium‐competitive acid blocker (P‐CAB) with a mechanism of
action distinct from that of the PPIs.14
Unlike PPIs, that require a chemical transformation into their active
form and bind covalently to the gastric H+/K+‐ATPase, tegoprazan
inhibits H+/K+‐ATPase in a reversible and K+‐competitive manner
without a need for any conversion. It is an acid‐resistant weak base
which can remain in a highly acidic canaliculi of gastric parietal cells.
Nonclinical studies have shown that this compound suppresses
gastric acid secretion faster and more potently than esomeprazole
treated group.14 The therapeutic potential of tegoprazan may be
derived from its ability to accumulate at high concentrations in the
canaliculi of gastric parietal cells. Consequently, it is slowly cleared
from the gastric glands and exerts its effects independent of acid
levels, leading to a strong and sustained effect.14 Tegoprazan has
been demonstrated a strong antisecretory potency and a fast onset
of action in several phase I studies.15 Its suppressive effect on acid
secretion reaches a maximum plateau within 0.5‐1 hour after admin-
istration at a dose of 50, 100 or 200 mg.15 The food effect on phar-
macodynamics and pharmacokinetics study indicated that the
efficacy of tegoprazan is independent of food intake.16 The pharma-
codyniamc data of tegoprazan indicate that the 50 and 100 mg
doses increase intragastric pH to ≥4 significantly more than the
dexlansoprazole 60 mg with evening dosing.17 In a phase II dose‐
ranging study, the proportions of patients with EE who were healed
up to week 8 were comparable between tegoprazan (50‐200 mg,
once daily) and esomeprazole (40 mg, once daily).18
On the basis of these phase I pharmacodynamics data and phase II
dose finding study in EE patients, it was hypothesised that treatment
with tegoprazan could produce at least comparable clinical efficacy in
healing of oesophagitis and symptom control compared with the treat-
ment of PPIs.
Esomeprazole has been shown to have better acid control than
lansoprazole, omeprazole and rabeprazole,19,20 and higher oesophagi-
tis healing rates than lansoprazole and omeprazole.21 Therefore,
esomeprazole 40 mg was considered to be the most appropriate
comparator to tegoprazan.
The purpose of this phase III study was to verify the non‐inferi-
ority of safety and efficacy of tegoprazan 50 and 100 mg to those
of esomeprazole 40 mg in patients with EE.
2 | MATERIALS AND METHODS
2.1 | Study design and treatments
Adult patients with endoscopically confirmed EE at screening were
eligible for enrolment into the 8‐week, double‐blind, three‐armed,
active‐controlled comparison study (ClinicalTrials.gov identifier
NCT03006874). The study was designed to verify the non‐inferiority
of tegoprazan 50 and 100 mg to esomeprazole 40 mg in patients
with EE. The study was conducted at 27 sites in South Korea from
October 2016 to August 2017.
The study protocol was approved by the Institutional Review
Board at each study site. The study was conducted in accordance with
the Declaration of Helsinki and the International Harmonisation on
Conference Harmonised Tripartite Guideline for Good Clinical Prac-
tice. All participants provided written informed consent before they
were enrolled. The participants were required to discontinue PPI use
during the screening period and throughout the study period. The
screening period was up to 14 days. Endoscopy was performed to
evaluate the presence and severity of EE based on the Los Angeles
(LA) Classification system during the screening period, and then at the
week 4, and week 8 or final visit (if not healed by week 4).
Following the screening period, patients were randomised 1:1:1
to receive either tegoprazan (50 or 100 mg) or esomeprazole
(40 mg). The doses were administered once daily for 4 or 8 weeks
via the oral route. Treatment was completed after 4 or 8 weeks if
healing of mucosal lesions was endoscopically confirmed.
2.2 | Study subjects
Male or female patients aged ≥20 years with endoscopically con-
firmed EE (LA Classification Grades A‐D) were eligible for inclusion in
the study. The major exclusion criteria included complications associ-
ated with oesophagitis, active gastric or duodenal ulcer, gastrointesti-
nal bleeding, Zollinger‐Ellison syndrome, malignancy, AIDS, hepatitis,
eosinophilic oesophagitis, a history of acid‐lowering surgery, previous
oesophageal or gastric surgery, malignancy within 5 years prior to
enrolment, primary oesophageal motility disorders, irritable bowel syn-
drome, inflammatory bowel disease or any of the following abnormal
laboratory test values at the screening (blood urea nitrogen and serum
creatinine level, >1.5 upper limit of normal [ULN]; total bilirubin level
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and serum levels of alanine aminotransferase, aspartate aminotrans-
ferase, alkaline phosphatase and gamma glutamyltransferase, >2ULN).
Pregnant and lactating subjects and those who needed treatment with
nonsteroidal anti‐inflammatory drugs or surgery requiring hospitalisa-
tion were excluded from the study. Any female of child‐bearing poten-
tial who was sexually active was required to use adequate
contraceptive measures during the study period. Patients were not
allowed to concomitantly use any medications that could affect effi-
cacy evaluation. These included proton pump inhibitors (within
2 weeks prior to enrolment), histamine receptor 2 blocking agents,
antidepressants, antipsychotics and antianxiety drugs.
2.3 | Study protocol
The patients were randomised to receive either tegoprazan or
esomeprazole. All randomisation information was securely stored
and could be accessed by authorised personnel only. A double‐
dummy method, using matching tegoprazan and esomeprazole pla-
cebo tablets, was employed to ensure that the study was double‐
blinded. All medications were provided in sealed boxes and supplied
by the medication supervisor to ensure blinded allocation.
At the start of the screening period, patient demographics and
other baseline characteristics were recorded, including medical his-
tory, concurrent medical conditions, medication history and concomi-
tant medications. At the start of the screening period, clinical
laboratory tests (complete blood count, serum chemistry and urinaly-
sis), physical examination, pregnancy test, electrocardiogram test and
Helicobacter pylori test were performed. In addition, vital signs were
assessed. At week 4 and 8 (or upon early termination), physical
examination, clinical laboratory tests and pregnancy test were per-
formed. Additionally, vital signs (including electrocardiogram [ECG]),
adverse events, concomitant medication, patients’ diary and treat-
ment compliance were checked.
Endoscopy was performed by principal investigators with at least
3 years of endoscopy experience at the start of the screening period
and at weeks 4 and 8 (or upon early termination). Severities of EE
were defined based on the endoscopic findings according to the LA
Classification from grade A to D. Healed EE was defined as the
absence of oesophageal mucosal erosions or ulcers on oesopha-
gogastroduodenoscopy. Changes in symptoms were assessed using
the Reflux Disease Questionnaire (RDQ), which is a 12‐item self‐ad-
ministered questionnaire designed to assess the frequency and
severity of heartburn, acid regurgitation and dyspepsia. Mean RDQ
score change was checked from baseline to week 4 or 8. Other
patient‐reported outcome measures included GERD Health‐Related
Quality of Life (GERD‐HRQL) scores, GERD symptoms and compli-
ance with treatment. The GERD‐HRQL scale has 11 items that focus
on heartburn symptoms, dysphagia, medication effects and the
patient's health condition. Each item is scored from 0 to 5, with a
higher score indicating a worse quality of life. Patients rated the
severity of heartburn and regurgitation at daytime and night‐time
according to the four‐point scale (0: none; 1: mild; 2: moderate; 3:
severe) using daily diaries.
2.4 | Outcome evaluation
The primary endpoint was the proportion of EE patients with healed
EE confirmed by endoscopy up to week 8. The secondary endpoints
included subjective symptoms, such as changes in RDQ scores, the
percentage of days without major symptoms as reported in the
patient's diary, GERD‐HRQL score, and the proportion of EE patients
with healed EE confirmed by endoscopy at week 4.
Safety was assessed by physical examinations and the analysis of
adverse events, laboratory test values, ECG findings and vital signs.
The frequency and severity of adverse events and concomitant med-
ications were monitored throughout the study. Treatment‐emergent
adverse event (TEAE) was defined as an adverse event occurred dur-
ing treatment, representing a change from baseline. All TEAEs were
graded based on severity as severe, moderate or mild by the investi-
gator. A drug‐related TEAE was an adverse event that was deemed
by the investigator as possibly related or as related to the study
drug. A serious TEAE was defined as an adverse event that could
cause death, hospitalisation, disability, congenital anomaly or a life‐
threatening adverse event.
2.5 | Statistical analysis
Based on the results of a phase II study in which the proportion of
EE patients showing healed EE up to week 8 was 96.0% for tego-
prazan 50 mg, 97.9% for tegoprazan 100 mg, and 96.1% for
esomeprazole 40 mg, the sample size in the present study was calcu-
lated 100 subjects per treatment group. A power of ≥90% was used
to detect non‐inferiority of tegoprazan to esomeprazole with a non‐
inferiority margin of 10%.
For the primary endpoint, the proportion of patients with healed
EE up to week 8 was calculated in the per protocol set (PPS) popula-
tion. The non‐inferiority of tegoprazan to esomeprazole was tested
by comparing the lower bound of two‐sided 95% confidence inter-
vals with a non‐inferiority margin of 10%. The same analyses were
performed for the proportion of patients with healed EE up to week
4. Wilcoxon's rank sum test was performed to compare the change
of symptom scores between groups.
Besides the PPS analysis (n = 271), the intention‐to‐treat (ITT)
analysis (n = 300) was also performed for efficacy analysis.
3 | RESULTS
3.1 | Study subjects
Out of the 452 patients enrolled in the study, 302 eligible patients
were randomised to receive either tegoprazan (50 mg, n = 100;
100 mg, n = 102) or esomeprazole (n = 100). A total of 286 subjects
completed the study (Figure 1).
The treatment groups were comparable regarding the baseline
characteristics except the history of smoking. EE severity at baseline
was similar between treatment groups (Table 1).
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The overall compliance rate exceeded 95% in all the treatment
groups. The mean compliance rates were 98.1%, 97.9% and 97.1%
in the tegoprazan 50 mg, tegoprazan 100 mg and esomeprazole
40 mg, respectively.
Sixteen patients (5.3%) did not complete the study: five in the
tegoprazan 50 mg group, four in the tegoprazan 100 mg group and
seven in the esomeprazole group. The details of each treatment
group are summarised in the flow chart in Figure 1.
3.2 | Healing rate of EE
In the PPS population, the proportion of patients with healed EE
over the 8‐week treatment period was 98.9%, 98.9% and 98.9% in
the tegoprazan 50 and 100 mg and esomeprazole 40 mg groups,
respectively. The lower bound of the two‐sided 95% confidence
interval of the treatment difference (tegoprazan‐esomeprazole) met
the prespecified non‐inferiority criteria (Table 2). Both doses of
Enrolled
(n = 452)
Inclusion/Exclusion criteria (n = 136)
Voluntary withdrawal (n = 14)
Randomized
(n = 302)
Tegoprazan 50 mg
(n = 100)
Tegoprazan 100 mg
(n = 102)
Esomeprazole 40 mg
(n = 100)
Completed
(n = 95)
Discontinuation
(n = 5)
Completed
(n = 98)
Discontinuation
(n = 4)
Completed
(n = 93)
Discontinuation
(n = 7)
Withdrawal (n = 2)
Adverse event (n = 2)
Use of contraindicated drug (n = 1)
Withdrawal (n = 1)
Adverse event (n = 2)
Use of contraindicated drug (n = 1)
Withdrawal (n = 1)
Adverse event (n = 3)
Inclusion/Exclusion criteria (n = 1)
Lost to follow-up (n= 2)
F IGURE 1 Randomisation protocol and patient disposition
TABLE 1 Demographic characteristics of the intention‐to‐treat population
Demographics
Tegoprazan Esomeprazole
50 mg (n = 99) 100 mg (n = 102) 40 mg (n = 99)
Age (y), mean (range) 52.7 (21.0‐74.0) 52.8 (20.0‐74.0) 50.4 (21.0‐75.0)
Males, n (%) 62 (62.6) 66 (64.7) 53 (53.5)
Height (cm), mean (range) 165.2 (142.5‐187.0) 166.1 (150.2‐183.0) 165.0 (145.3‐189.0)
Weight (kg), mean (range) 66.8 (43.0‐110.8) 66.4 (42.5‐112.5) 65.5 (40.7‐99.5)
Alcohol consumption, n (%) 42 (42.4) 45 (44.1) 39 (39.4)
Smoking, n (%) 27 (27.3) 17 (16.7) 13 (13.1)
Helicobacter pylori infection status positive, n (%) 23 (23.2) 21 (20.6) 21 (21.2)
Baseline LA Classification grade A, n (%) 66 (66.7) 67 (65.7) 66 (66.7)
Baseline LA Classification grade B, n (%) 29 (29.3) 30 (29.4) 29 (29.3)
Baseline LA Classification grades C/D, n (%) 4 (4.0) 5 (4.9) 4 (4.0)
LA, Los Angeles.
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tegoprazan were non‐inferior to esomeprazole 40 mg (P < 0.0001).
In the ITT analysis, the healing rates up to week 8 were comparable
between the tegoprazan (50 and 100 mg) and esomeprazole (40 mg)
groups. There were no statistically significant differences between
the treatment groups (Table 2).
In the PPS population, the proportion of patients with healed EE
over the 4‐week treatment period was 91.3% and 93.4% in the
tegoprazan 50 and 100 mg groups, respectively, which were similar
to that of the esomeprazole group (94.3%). The healing rate at week
4 in the ITT analysis was 87.9% in the tegoprazan 50 mg group
(n = 99), 90.2% in the tegoprazan 100 mg group (n = 102) and
87.9% in the esomeprazole 40 mg group (n = 99). In the ITT analysis,
tegoprazan 50 and 100 mg were non‐inferior to esomeprazole
40 mg (P = 0.0156 and 0.0026, respectively).
3.3 | Symptom response
Patients in all the three treatment groups reported significant
improvement in the severity and frequency of heartburn, dyspepsia
and regurgitation, which were assessed at weeks 4 and 8 using RDQ
scores (P < 0.0001). Mean RDQ severity and frequency scores sig-
nificantly decreased after the 4‐ and 8‐week treatments with the
investigational drugs. There were no significant differences between
the treatment groups regarding mean changes in RDQ total scores
at either week 4 or 8. Mean reductions in the severity/frequency of
heartburn and dyspepsia did not show statistically significant differ-
ences between the treatment groups at week 8.
Reductions in the regurgitation severity and frequency were
statistically higher in the tegoprazan 50 mg group at week 4 and 8
than in the esomeprazole 40 mg group. However, significant differ-
ence (P‐value) of regurgitation at baseline was observed between
the treatment groups, and the least‐squares mean change in the
regurgitation score from baseline to week 4 or 8 was analysed
additionally. There was no statistically significant difference
between the three treatment groups after adjustment of baseline
(Table 3).
There was a significant increase in the percentage of days with-
out major symptoms (heartburn and regurgitation) in all the treat-
ment groups, but there were no statistically significant differences
between the treatment groups (data not shown). GERD‐HRQL total
scores over the 4‐ and 8‐week treatment periods reduced
significantly in all the treatment groups. The mean reduction in
GERD‐HRQL scores of the tegoprazan‐treated groups was not signif-
icantly different from that in the esomeprazole‐treated group
(Table 4).
3.4 | Tolerability and safety
Three hundred patients received at least one dose of a study medi-
cation and were included in the safety analyses. Most TEAEs (136/
149, 91.3%) were mild in intensity. Two severe TEAEs that were
joint injury and breast cancer in the tegoprazan 50 mg group that
were “definitely not related” to the investigational drug. There were
no severe TEAEs in the tegoprazan and esomeprazole groups. The
percentages of patients with more than one TEAE were 28.3%,
23.5% and 30.3% in the tegoprazan 50 mg, tegoprazan 100 mg and
esomeprazole 40 mg groups, respectively (Table 5). Drug‐related
TEAEs (≥2%) are shown in Table 6. Dyspepsia (2.0%) and chest dis-
comfort (2.0%) in the tegoprazan groups, and headache (4.0%) in the
esomeprazole group were the most frequently reported drug‐related
TEAEs (Table 6). All the TEAEs disappeared spontaneously without
any treatment. The percentage of patients with TEAEs leading to
premature discontinuation of treatment was 2.9% in the tegoprazan
50 mg group, 2.9% in the esomeprazole 40 mg group and 3.0% in
the tegoprazan 100 mg group. Headache (2% in the esomeprazole
40 mg group) was the most common adverse event that led to dis-
continuation. The rate of serious TEAEs was 2.0% in the tegoprazan
50 mg group, 2.0% in the tegoprazan 100 mg group and 1.0% in the
esomeprazole 40 mg group. All serious TEAEs were considered to be
unrelated to the study medication by the investigators. No signifi-
cant changes in vital signs or ECG findings were observed during the
study period.
TABLE 2 Healing rates (%) of erosive oesophagitis up to week 8
Treatment
%
Patients
healed
Difference
from
esomeprazole [95% CIs]
P‐valuea
non‐
inferiority
Week 8 PPS
Tegoprazan
50 mg
98.9 0.1 [−3.0, 3.1] <.0001
Tegoprazan
100 mg
98.9 0.0 [−3.0, 3.1] <.0001
Esomeprazole
40 mg
98.9
ITT
Tegoprazan
50 mg
96.0 3.0 [−3.3, 9.4] <.0001
Tegoprazan
100 mg
95.1 2.2 [−4.4, 8.7] 0.0001
Esomeprazole
40 mg
92.9
Week 4 PPS
Tegoprazan
50 mg
91.3 −3.0 [−10.5, 4.5] 0.0343
Tegoprazan
100 mg
93.4 −0.9 [−7.9, 6.1] 0.0056
Esomeprazole
40 mg
94.3
ITT
Tegoprazan
50 mg
87.9 0.0 [−9.1, 9.1] 0.0156
Tegoprazan
100 mg
90.2 2.3 [−6.3, 11.0] 0.0026
Esomeprazole
40 mg
87.9
CIs, confidence intervals; ITT, intention‐to‐treat; PPS, per protocol set.
aNon‐inferiority test at the significant level 0.05 (two‐sided).
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4 | DISCUSSION
The findings of the current randomised controlled study in 302
patients with EE demonstrated that tegoprazan, when administered
at 50 or 100 mg once daily, was non‐inferior to esomeprazole 40 mg
regarding the healing rate of EE. Both doses of tegoprazan were
highly effective in healing EE. Tegoprazan 100 mg did not provide
additional clinical benefit over tegoprazan 50 mg. However, we did
not observe any superior results of tegoprazan over esomeprazole
since the healing rates in all treatment groups were too high to
detect any significant differences.
The healing rates after 4 weeks of treatment were also compara-
ble between the treatment groups, and higher than 90% in all treat-
ment groups. ITT analyses of the healing rate after the 4‐week
treatment demonstrated the non‐inferiority of tegoprazan 50 mg to
esomeprazole 40 mg.
All these results are consistent with those of a previous phase II
dose‐ranging study in EE patients.18 Subgroup analysis according to
the baseline LA grade of oesophagitis revealed no significant differ-
ences in healing rates between the two doses of tegoprazan and
esomeprazole 40 mg at week 4 and 8 (data not shown).
Treatment with tegoprazan also showed high healing rates
(100%) in EE patients with LA grade C/D, although the number of
those patients was small (n = 3‐4/group). In South Korea, most of
patients with EE have LA grade A or B. Patients with LA grade C or
D are relatively rare.22,23
Currently, two P‐CABs including tegoprazan have been approved
for the treatment of GERD. Revaprazan, the first P‐CAB was
approved for treating peptic ulcers.24,25 The second P‐CAB clinically
available was vonoprazan, which was recently approved for the
treatment of EE in Japan.26–28 Tegoprazan was approved in South
Korea in July, 2018 for the treatment of EE and NERD, and it
became the first P‐CAB clinically available for treating NERD.29,30
The present study showed that RDQ scores assessing the sever-
ity and frequency of regurgitation significantly decreased more in
the tegoprazan 50 mg group than in the esomeprazole group
(P < 0.05, Wilcoxon's rank sum test). However, there was significant
difference in the baseline score at the baseline between treatment
groups. We analysed the regurgitation score change from baseline to
4 or 8 week using Least square mean (data now shown), and found
that there was no significant difference of the regurgitation score
change among the three treatment groups.
Both tegoprazan and esomeprazole were well tolerated in the
current study. Two patients in the tegoprazan 50 mg group, two in
the tegoprazan 100 mg group and three in the esomeprazole group
discontinued treatment because of TEAEs. Dyspepsia and chest
TABLE 3 Mean RDQ symptom scores at baseline, week 4 and 8 (per protocol set)
Mean RDQ
Tegoprazan Esomeprazole
50 mg (n = 92) 100 mg (n = 91) 40 mg (n = 88)
Severity Baseline Week 4 Week 8 Baseline Week 4 Week 8 Baseline Week 4 Week 8
Major symptom 2.00 0.58 0.58 1.87 0.58 0.58 1.72 0.50 0.48
Heartburn 1.76 0.53 0.56 1.86 0.62 0.62 1.84 0.48 0.47
Dyspepsia 1.43 0.41 0.40 1.47 0.38 0.37 1.47 0.45 0.45
Regurgitation 2.24 0.62 0.60 1.88 0.54 0.54 1.61 0.52 0.50
Frequency
Major symptom 2.02 0.88 0.87 2.01 0.85 0.84 1.82 0.78 0.75
Heartburn 1.75 0.79 0.79 1.97 0.92 0.90 1.89 0.76 0.74
Dyspepsia 1.54 0.52 0.51 1.49 0.52 0.49 1.57 0.61 0.62
Regurgitation 2.29 0.97 0.95 2.05 0.77 0.77 1.75 0.79 0.76
RDQ, Reflux Disease Questionnaire.
TABLE 4 GERD‐HRQL score changes from baseline at week 4 and week 8 (per protocol set)
GERD‐HRQL
Tegoprazan Esomeprazole
50 mg (n = 92) 100 mg (n = 91) 40 mg (n = 88)
Week 4 Week 8 Week 4 Week 8 Week 4 Week 8
Change from baseline −7.9 −8.1 −7.3 −7.3 −6.9 −7.1
P‐valuea <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Difference from esomeprazole −1.0 −1.0 −0.4 −0.2 — —
P‐valueb 0.1858 0.1920 0.7560 0.8216 — —
GERD‐HRQL, Gastro‐oesophageal Reflux Disease Health‐Related Quality of Life.
aWilcoxon's signed rank test.
bWilcoxon's rank sum test.
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discomfort were drug‐related TEAEs with an incidence of ≥2% in
the tegoprazan 50 mg group (Table 6). Headache was the most fre-
quently reported drug‐related TEAE in the esomeprazole 40 mg
group, that was the only drug‐related TEAE showing a significant
difference compared to the other group (P = 0.0196). Diarrhoea
was the most frequent TEAE in the tegoprazan 50 and 100 mg
groups. However, there was no significant difference in the occur-
rence rate of diarrhoea between the three treatment groups
(P = 0.3093).
Furthermore, there were no newly identified safety signals or any
significant changes in vital signs, ECG findings or other safety signals.
Overall, all the treatments were well tolerated. Moreover, the inci-
dences of TEAEs, drug‐related TEAEs, serious TEAEs and TEAEs lead-
ing to drug discontinuation were similar between the tegoprazan‐ and
esomeprazole‐treated groups. The majority (91.3%) of TEAEs were
considered mild in severity and not related to the study drug.
In conclusion, once daily administration of tegoprazan 50 or
100 mg shows non‐inferior efficacy in healing EE and tolerability to
that of esomeprazole 40 mg.
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TABLE 5 Summary of treatment‐emergent adverse events (TEAEs)
Tegoprazan Esomeprazole
50 mg (n = 99) 100 mg (n = 102) 40 mg (n = 99)
n (%) [F] n (%) [F] n (%) [F]
Any TEAE 28 (28.3) [43] 24 (23.5) [55] 30 (30.3) [51]
Drug‐related TEAE 10 (10.1) [17] 5 (4.9) [14] 11 (11.1) [14]
Serious TEAE 2 (2.0) [2] 2 (2.0) [2] 1 (1.0) [1]
Death 0 (0.0) [0] 0 (0.0) [0] 0 (0.0) [0]
Most frequently reported TEAEs by system organ class and preferred term a P‐value
Gastrointestinal disorders 10 (10.1) 9 (8.8) 10 (10.1) 0.9390b
–Diarrhoea 3 (3.0) 5 (4.9) 1 (1.0) 0.3093b
Nervous system disorders 0 (0.0) 2 (2.0) 7 (7.1) 0.0087c
–Headache 0 (0.0) 2 (2.0) 6 (6.1) 0.0220c
Infections and infestations 6 (6.0) 8 (7.8) 9 (9.1) 0.7229b
–Viral upper respiratory tract infection 4 (4.0) 6 (5.9) 6 (6.1) 0.7818b
[F] = Frequency of TEAEs
N‐dash represents preferred term.
a≥3%
bChi‐square test
cFisher's exact test.
TABLE 6 Drug‐related treatment‐emergent adverse events
(TEAEs) reported by at least 2% of patients in any treatment group
System organ class/
Preferred term
Tegoprazan Esomeprazole
P‐
valuea
50 mg
(n = 99)
n (%)
100 mg
(n = 102)
n (%)
40 mg
(n = 99)
n (%)
Dyspepsia 2 (2.0) 1 (1.0) 0 (0.0) 0.5467
Chest discomfort 2 (2.0) 0 (0.0) 1 (1.0) 0.3245
Headache 0 (0.0) 1 (1.0) 4 (4.0) 0.0196
aFisher's exact test.
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